



## Translation

**Roche Diagnostics K.K.  
6-1 Shiba 2-chome, Minato-ku, Tokyo**

**Chugai Pharmaceutical Co., Ltd.  
1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo**

### **Roche Diagnostics and Chugai Pharmaceutical Present a Biology Science Laboratory Targeting High School Students**

**August 23, 2013 (Tokyo)- Roche Diagnostics K.K. (Head Office: Minato-ku, Tokyo; President and CEO: Makoto Ogasawara) (hereafter, "RDKK") and Chugai Pharmaceutical Co., Ltd. (Head Office: Chuo-ku, Tokyo; Chairman and CEO: Osamu Nagayama) (hereafter, "Chugai") presented a biology science laboratory targeting high school students entitled, "What meat is this? Verification of beef, pork and poultry contained in foods, using real-time PCR," as the part of their company's social contribution activities.**

For two days from August 21 to 22, a biology science laboratory entitled, "What meat is this? Verification of beef, pork and poultry contained in foods, using real-time PCR" was held at the Science Museum, Tokyo, a facility managed by the Japan Science Foundation. A total of XX high school students took part in the class and conducted an experiment on genetic analysis by actually using the latest Real-time PCR amplification and detection instrument.

The students used the meat contained in foods they had brought on that day, such as hamburger and gyoza dumplings, crushed them as samples, extracted DNA from the supernatant solution, then set it on the Real-time PCR amplification and detection instrument., together with reagents, allowed it to react, and detected the type of genes contained in the samples, namely, beef, pork or poultry. It appeared that, by analyzing the genes of foods which they were eating from day to day, the students who took part in the experiments were able to relate even more to words such as genes and genetic testing.

RDKK and Chugai are members of the Roche Group, a global healthcare company that is headquartered in Switzerland. Until now, they have been carrying out a wide range of activities from the perspective of contributing to fostering and training people who will be playing a leading role in science and technology of the next generation. The two companies have collaborated for the first time and carried out this science laboratory, making it possible to provide opportunities for high school students to deepen their interest in science. RDKK and Chugai will continue to actively engage in educating the next generation of people as the part of their company's social contribution activities.

## 【Overview of the Science Laboratory】

Name of the event:

Roche Diagnostics and Chugai Pharmaceutical present a Biology Science Laboratory:  
“What meat is this?”

Dates held:

Wednesday, August 21, 2013 from 1:00 p.m. to 4:30 p.m.

Thursday, August 22, 2013 from 1:00 p.m. to 4:30 p.m.

Venue:

Experimental Stadium, 4<sup>th</sup> floor, the Science Museum, Tokyo

Participation:

Free of charge

Participation targets:

High school students and older



Please address inquiries to:

Roche Diagnostics K.K. Communications:

Tel 03-5443-7040 Fax 03-5443-7113

Chugai Pharmaceutical Co., Ltd. Corporate Communications Dept. Media Relations Group:

Tel 03-3273-0881 Fax 03-3281-6607

## 【Corporate Profile】

### About RDKK

Roche Diagnostics K.K. is the Japanese affiliate of the Diagnostics Division of F. Hoffmann-La Roche Ltd based in Basel, Switzerland, one of the world's leading healthcare companies. With 817 employees, sales branches and a logistics center in 9 cities in Japan (as of Feb. 2013), we are involved in wide range of healthcare areas such as In-vitro Diagnostics, Applied Science and Diabetes Care. We provide effective solutions which increase medical value and efficiency of clinical testing to enable healthcare professionals to make the best treatment selections.

Please visit [www.roche-diagnostics.jp](http://www.roche-diagnostics.jp)

## **About Chugai**

Chugai Pharmaceutical is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.

In Japan, Chugai's research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and Ukima is conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research was established in Singapore in January 2012 for conducting research focusing on the generation of new antibody drugs by utilizing Chugai's proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.

The consolidated revenue in 2012 of Chugai totaled 391.2 billion yen and the operating income was 76.4 billion yen. We are aiming at the consolidated revenue of 416.0 billion yen and operating profit of 77.5 billion yen in IFRS core basis, in 2013.

Additional information is available on the Internet at <http://www.chugai-pharm.co.jp/english>.